Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting early-phase tilt top decile by trial count

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair: 10 sponsored US clinical trials, none currently recruiting.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is SCLC, with 1 trials.

Top-decile sponsor footprint

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

NCT05987956
ACTIVE NOT RECRUITING Early Phase 1

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

NCT07182838
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

NCT07145333
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

NCT01064466
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

NCT06062810
ACTIVE NOT RECRUITING Phase 2

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585
ACTIVE NOT RECRUITING Early Phase 1

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

NCT03305341
ACTIVE NOT RECRUITING Early Phase 1

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

NCT06959563
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

NCT03348670
ACTIVE NOT RECRUITING Phase 1

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

NCT02403505

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 6

Therapeutic Areas

SCLC 1
HPV Infection 1
Type 2 Diabetes 1
HIV Infections 1
Rectal Cancer 1
Breast Cancer 1
COVID-19 1
Small-cell Lung Cancer 1
Prostate Cancer 1

How the Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: SCLC (1 trial), 8 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair page

10 registered trials is a research-attention snapshot, not an endorsement of Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair or any single study.

  • None of Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • SCLC is the condition Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair studies most, compare against other sponsors active in the same condition before evaluating a specific study. See SCLC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.